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Background: Recent studies have indicated that the nuclear RNA-binding protein RBM5 has the ability to modulate
apoptosis and suppress tumor growth. The aim of this study is to investigate the expression of RBM5 in human
prostate cancer and its mechanism of tumor suppression.
Methods: The expression of RBM5 protein in cancerous prostatic tissues and normal tissues was examined by IHC.
PC-3 cell line was used to determine the apoptotic function of RBM5 in vitro. PC-3 cells were transiently transfected
with pcDNA3.1-RBM5. Cell viability was determined by MTT assay. Rhodamine 123 staining and Annexin V analysis
were performed to observe the apoptotic activity of PC-3 cells overexpressing RBM5. Expression of
apoptosis-related genes was assessed by western blot.
Results: The expression of RBM5 protein was significantly decreased in cancerous prostatic tissues compared to the
normal tissues. PC-3 cells overexpressing RBM5 showed not only significant growth inhibition compared with the
vector controls, but also dysfunction of mitochondrial membrane potential and increased apoptotic activity. To
further define RBM5 function in apoptotic pathways, we investigated differential expression profiles of various
BH3-only proteins including Bid, Bad, and Bim, and apoptosis regulatory proteins include P53, cleaved caspase9,
and cleaved caspase3. We found that the expression of both BH3-only proteins and apoptosis regulatory proteins
was increased in RBM5 transfected cells.
Conclusion: The expression of RBM5 protein was significantly decreased in cancerous prostatic tissues, which
suggests that RBM5 plays an important role in the pathogenesis of prostate cancer. RBM5 may induce the
apoptosis of prostate cancer PC-3 cells by modulating the mitochondrial apoptotic pathway, and thus RBM5 might
be a promising target for gene therapy on prostate cancer.
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Prostate cancer (PCa) is the second most common cause of
cancer and the sixth leading cause of cancer death among
men worldwide with an estimated 899,000 new cases and
258,000 new deaths in 2008. The worldwide PCa burden is
expected to grow to 1.7 million new cases and 499,000 new
deaths by 2030 simply due to the growth and aging of the
global population [1]. In China, the incidence of prostate
cancer has increased over time [2]. Surgery and radiotherapy* Correspondence: kewangm1@hotmail.com
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reproduction in any medium, provided the orwith or without androgen deprivation therapy are the
most effective therapeutic strategies for localized disease
[3]. However, there is currently no effective treatment
strategy for patients with advanced prostate cancer at
diagnosis and those who do not respond to primary cura-
tive attempts. Chemotherapeutic drugs can only extend
the lives of patients with advanced prostate cancer by
months, and they are also associated with dose-related
toxicity and the emergence of tumor cell resistance to the
drugs. It is imperative to develop novel, more effective
strategies to treat prostate cancer. With the recent
advances in the understanding of molecular pathways
involved in prostate cancer progression, targeted therapiestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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therapeutics.
RNA-binding motif protein 5 (RBM5) is a gene which
maps to human chromosome 3p21.3, a critical region
which is deleted in a large number of human cancers and
which is predicted to contain one or more tumor suppres-
sor genes (TSGs) [4,5]. The expression level of RBM5 was
shown to be high in the adult thymus and low in the fetal
thymus, indicating that RBM5 expression may be develop-
mentally regulated [6]. Previous studies have shown that
RBM5 mRNA and protein expression was frequently
reduced in different cancers, including ras-transformed
Rat-1 embryonic fibroblastic cells [7], breast cancer [8],
human vestibular schwannoma [9], and primary lung can-
cer specimens [10,11]. A number of lines of evidence indi-
cate involvement of RBM5 and its splice variants in
apoptosis, cell proliferation, and oncogenesis [12,13].
Introduction of RBM5 cDNA into human breast cancer
cells deleted of 3p21.3 reduced both anchorage-dependent
and -independent cell growth in vitro [10]. The ectopic
expression of RBM5 suppresses the growth of human lung
cancer [14,15], breast cancer [16], renal tumors [17], fibro-
sarcoma [8], and hematopoietic cells [7,18,19].
These observations suggest that changes in either the
level of expression of RBM5, or in the processing of its
mRNA, have profound consequences for cellular behav-
ior and suggest a role for RBM5 as one of the tumor
suppressor genes. Although the mechanisms of RBM5-
mediated tumor suppression remain unknown, recent
studies suggest that RBM5 is involved in the regulation
of the apoptosis pathway [12,13]. Defects in apoptosis
underpin both tumorigenesis and drug resistance [20].
However, the role of RBM5 in prostate cancer has yet to
be elucidated.
Hormone-refractory prostate cancer (HRPC), resistant
to hormone therapy, is a major obstacle in clinical
treatment [21]. Accordingly, the approach for HRPC
treatment is deeply demanded. In this study, we focused
our research specifically on HRPC cell line PC-3 cells.
In the preliminary work, our group had found that
human lung cancer tissues expressed less RBM5 than
normal tissues did [11], and overexpression of RBM5
can inhibit the proliferation and induce the apoptosis of
human lung cancer A549 cells [15]. In this study, we
hypothesized that RBM5 may be involved in human
prostate cancer cells. Our research revealed that overex-
pression of RBM5 induced the apoptosis of prostate
cancer PC-3 cells by promoting the mitochondrial
apoptotic pathway, activating the caspase-9- and
caspase-3-dependent apoptosis. These findings suggest
that RBM5 may act as a prognostic indicator in pros-
tate cancer patients, as well as act as a molecular target
for gene therapy.Methods
Prostate tissue acquisition and immunohistochemistry
staining (IHC)
Prostate cancer specimens were obtained from patients
undergoing prostatectomy in the Second and the Third
Affiliated Hospitals of Jilin University, the Gleason
scores for which were from grade 7 to grade 8. Normal
prostate tissues were obtained from patients undergoing
surgery for benign prostatic hyperplasia (BPH) in these
hospitals. This study was approved by the Research Eth-
ics Committee of Norman Bethune College of Medicine,
Jilin University and was in compliance with the Helsinki
Declaration. The tissues were examined by the patholo-
gists to confirm the diagnosis before IHC analyses. All
specimens were fixed in 10% formalin, embedded in par-
affin, and cut into 4-μm-thick slides. The slides were
dewaxed, and the endogenous peroxidase activity was
blocked by treatment with 3% hydrogen peroxide solu-
tion in methanol for 20 min. Non-specific binding was
prevented by blocking with normal goat serum (1:10) for
10 min. The staining procedure was carried out using an
avidin-biotin-peroxidase complex method. The presence
of RBM5 was evaluated by staining with rabbit anti-
RBM5 antibody (Abcam, Cambridge, MA, USA). After
incubation with the primary antibody for 60 min, the
slides were incubated with the biotinylated goat anti-
rabbit IgG (H+L) (DAKO, Carpinteria, CA, USA) at
37°C for 30 min, followed by incubation with a 1:200
streptavidin-biotin-peroxidase complex (Sigma, St.
Louis, MO, USA) for 30 min. Reactive products were
visualized with 3,30-diaminobenzidene (DAB) as the
chromogen, and the slides were counterstained with
hematoxylin. Sections previously known to express
RBM5 were included in each run, receiving either the
primary antibody as the positive control, or a mouse IgG
as the negative control. The stained slides were analyzed
with a microscope at 400× magnification. Cellular
brownish staining was scored as positive and the thresh-
old was set at 10%.
Cell culture and transfection
The human prostate cancer cell line PC-3 was obtained
from the American Type Culture Collection (ATCC,
Rockville, MD, USA) and incubated at 37°C with hu-
midified 5% CO2 in IMDM (Hyclone, UT, USA) supple-
mented with 10% fetal bovine serum (Hyclone, UT,
USA), 100 unit/mL of penicillin, 100 μg/mL of strepto-
mycin, and 2 mM of L-glutamine. 5 × 105 cells were pla-
ted onto 6-well plates 24 h before transfection. The
pcDNA3.1-RBM5 and pcDNA3.1 plasmids were pro-
vided by Dr. Leslie C. Sutherland from Research Pro-
gram, Northeast Cancer Centre, Health Sciences North
in Canada. PC-3 cells were transfected using lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA, USA) with 4 mg
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Transfection media were removed 6 h after transfection
and replaced with fresh complete medium containing
10% fetal bovine serum (FBS). Controls included lipofec-
tamine 2000 treated cells and empty vector pcDNA3.1
transfected cells.
Semi-quantitative reverse transcription PCR (RT-PCR) and
western blot analysis
PC-3 cells were divided into three groups: (a) control
(mock-transfected); (b) EV (transfected with empty vector
pcDNA3.1); (c) RBM5 (transfected with pcDNA3.1-
RBM5), and cells were harvested after 48 h following trans-
fection and treatment. Overexpression of RBM5 mRNA
and protein was confirmed by RT-PCR and western blot.
For semi-quantitative RT-PCR, total RNA was extracted
from the cells using the Trizol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. First-strand cDNA was generated by reverse
transcription of 1 μg RNA samples using a SuperScript
pre-amplification system (Promega, Madison, MI, USA).
One-tenth of the reverse-transcribed RNA was used in the
PCR reaction. The primer sequences were as follows:
GAPDH sense: 50-GAAGGTGAAGGTCGGAGTC-30 and
antisense: 50-GAAGATGGTGATGGGATTTC-30; RBM5
sense: 50-GCACGACTATAGGCATGACAT-30 and anti-
sense: 50-AGTCAAACTTGTCTGCTCCA-30. The PCR
products were separated by electrophoresis on 1% agarose
gels. The PCR products were visualized by a Tanon-1600
figure gel image processing system and analyzed with a
GIS 1D gel image system software (Tanon, Shanghai,
China).
For western blot analysis, cells were lysed with HEPES
lysis buffer. The cell lysates were then centrifuged for 30
min at 12,000×g and the protein concentrations were
determined using the Protein Assay Kit (Bio-Rad,
Hercules, CA, USA). Forty micrograms of protein were
separated by 10% SDS-PAGE gel and transferred onto a
PVDF membrane (Millipore, Bedford, MA, USA). The
membranes were blocked with 5% non-fat milk for 1 h
at room temperature and probed with antibodies of anti-
RBM5 (Abcam, Cambridge, MA, USA), anti-Caspase3
(Cell Signaling Technology, Boston, MA, USA), anti-
Caspase9 (Cell Signaling Technology, Beverly, MA,
USA), anti-Bid, anti-Bim, anti-Bad (Cell Signaling Tech-
nology, Danvers, MA, USA), and anti-β-actin (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) overnight at
4°C. Horseradish peroxidase-conjugated secondary anti-
bodies (Thermo, Waltham, MA, USA) at a dilution of
1:2,000 were then applied for 1 h at room temperature.
The protein bands were then detected using an
Enhanced Chemiluminescece kit (Pierce Biotechnology
Ltd., Rockford, IL, USA). The protein levels werequantified by densitometry using Quantity One software
(Bio-Rad).
Cell viability assays
Cell viability was determined using 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays.
The cells were plated onto 96-well plates at a concentra-
tion of 1×104 cells per well for 24 h and then transfected
with pcDNA3.1 or pcDNA3.1-RBM5 for 24 h, 48 h, and
72 h. The cells were treated with 0.5 mg/mL MTT
(Sigma-Aldrich, St. Louis, MO, USA) solution for 4 h.
The medium was removed, and 100 mL of dimethylsulf-
oxide was added to each well. The formazan dye crystals
were solubilized for 15 min and the optical density was
measured at 570 nm with a Vmax Microplate Reader
(Molecular Devices, Sunnyvale, CA, USA). Cell viability
was calculated as a percentage of the control (untreated)
values. Experiments were repeated three times with each
experiment containing triplicate samples.
Rhodamine123 staining for mitochondria membrane
potentials
Mitochondria membrane potentials were assessed by
Rhodamine123 (Sigma-Aldrich, St. Louis, MO, USA)
staining. After transfected by plasmid for 48 h, PC-3 cells
were incubated with 2 μM Rhodamine123 at 37°C for 30
min, washed with phosphate-buffer solution, and exam-
ined using a fluorescence microscope (Olympus, Japan)
to observe the mitochondria membrane potentials.
Flow cytometry analysis of apoptosis
After transfected by plasmid for 48 h, PC-3 cells were
trypsinized and centrifuged, washed, and stained using
the Annexin-V-FITC Apoptosis Detection Kit (Beyotime,
Shanghai, China). The samples were then analyzed for
apoptosis by a FACScan flow cytometer (Becton
Dickinson, Franklin Lakes, NJ, USA). Annexin-V-FITC
(−)/PI(−) was used to indicate cells that had survived,
Annexin-V-FITC(+)/PI(−) was used to indicate cells that
were in the early stage of apoptosis, and Annexin-V-
FITC(+)/PI(+) was used to indicate cells in the late stages
of apoptosis or necrosis.
Statistics
Chi-square test was used to analyze the difference in
RBM5 expression between normal and cancerous pros-
tate tissues. Data were presented as mean ± standard de-
viation (SD) when appropriate. The regression analysis
was performed with SPSS software (version 17.0). Com-
parisons between treatments were made using a paired
Student’s t-test, or one-way ANOVA for multiple group
comparisons. A P value of <0.05 was considered statisti-
cally significant.
Figure 2 Overexpression of RBM5 in PC-3 cells. PC-3 cells were
transfected with pcDNA3.1 or pcDNA3.1-RBM5 plasmids for 48h.
RT-PCR and western blot were performed respectively to determine
the RBM5 mRNA (A) and protein levels (C). Data shown are
means±S.D. of three separate experiments (C for mRNA and D for
protein). * indicates significant difference as compared to the mock
control and EV (P <0.01).
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Prostate cancer tissues expressed less RBM5
We first analyzed the expression of RBM5 by IHC staining
in a collection of prostate cancer and normal tissues in a
Chinese cohort. As shown in Figure 1, the RBM5 protein
was virtually undetectable in prostate cancer but highly
expressed in normal prostatic tissue. The cellular localization
of RBM5 is mostly cytoplasmic. Overall, RBM5 was
expressed in 10 of 11 (90.9%) normal prostate tissues, and
the cytoplasmic/nuclear ratio of the staining was about 50%;
while the RBM5 was expressed in two of 12 prostate cancer
specimens (16.7%), and the cytoplasmic/nuclear ratio of the
staining was about 10%. The difference is statistically sig-
nificant (P <0.01). These results indicated that RBM5 is
less-expressed in clinical prostate cancers, suggesting
RBM5 is a promising target for prostate cancer therapy.
RBM5 was overexpressed in pcDNA3.1-RBM5 transfected
PC-3 cells
As a eukaryotic expression, pcDNA3.1 can transfer the ec-
topic gene into cells, and express the interest protein in the
target cells. In this study, we employed PC-3 cells to investi-
gate the function of RBM5 in prostate cancer cells.
After transfection with pcDNA3.1 vector and pcDNA3.1-
RBM5 vector, semi-quantitative RT-PCR and western blot
were performed to analyze the expression of RBM5
mRNA and protein. As shown in Figure 2A and 2B, the
expression of RBM5 mRNA increased significantly in trans-
fected pcDNA3.1-RBM5 cells compared with transfected
pcDNA3.1 vector and mock control cells (treated with
lipofectamine 2000 only) (P <0.01). Western blot assay
showed a similar and statistically significant increase
(P <0.01) (Figure 2C and 2D). The result demonstrated that
RBM5 was effectively overexpressed in the pcDNA3.1-
RBM5 transfected cells (RBM5), compared with the cells
transfected with empty vector pcDNA3.1 (EV).
Overexpression of RBM5 inhibited proliferation
of PC-3 cells
To explore the effect of RBM5 overexpression on cell
growth, MTT assays were performed at 24 h, 48h, andFigure 1 Immunohistochemistry staining of RBM5 in normal and canc
The images were obtained at 400 × magnifications, brown color represent72 h, respectively, after the transfection. Results showed
that there was a significant inhibition of cell proliferation
in RBM5 overexpressing PC-3 cells compared with the
mock control and EV groups (Figure 3A). Along with
the extension of the time, the inhibition rate was
increased, and at 72 h, the inhibition rate had been more
than 30% (data not shown).
To further explore the effect of RBM5 overexpression on
proliferation of PC-3 cells, Immunocytochemistry staining
was employed to detect the expression of PCNA after
transfected. As shown in Figure 3B, the staining results
showed that the lowest numbers of proliferating cells
(PCNA positive) were found in pcDNA3.1-RBM5 trans-
fected group. Quantitative analyses of the stained slides
were performed and the results are summarized in
Figure 3C. The proliferation index was defined as percent
of tumor cells stained positively for PCNA. In RBM5 group,
the proliferation index was significantly lower (P <0.01),
when compared with the control groups.erous prostatic tissue. (A) Normal prostate. (B) Prostate cancer.
s RBM5 staining.
Figure 3 RBM5 inhibits proliferation of PC-3 cells. PC-3 cells were transfected with pcDNA3.1 or pcDNA3.1-RBM5 plasmids for up to 24 h and
48 h. Afterwards, (A) cell growth was evaluated by MTT assay. The data were presented as optical density in different groups. Data shown are
means ± S.D. of three separate experiments. (B) Immunocytochemistry staining of PCNA. (C) Proliferation index of PCNA. * indicates significant
difference as compared to the control and EV (P <0.05).
Figure 4 RBM5 induces dysfunction of mitochondrial membrane potential and modulates apoptosis of PC-3 cells. (A) Morphological
images of PC-3 cells transfected with pcDNA3.1 and pcDNA3.1-RBM5. (B) Analysis of mitochondrial membrane potential by Rhodamine123
staining in PC-3 cells under the fluorescence microscope. (C) Flow cytometry analysis of apoptosis by Annexin V staining. The representative data
of FCM with Annexin V and PI staining for detecting apoptotic cells were shown in controls and RBM5-transfected groups. Q1 represents normal
cells, Q2 and Q3 represent early and late apoptotic cells, respectively, Q4 represents necrotic cells.
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To determine the contribution of inhibition of cell
growth induced by RBM5 overexpression, we employed
Rhodamine 123 staining and flow cytometry analysis to
determine apoptotic activity in PC-3 cells. Rhodamine
123 can easily be absorbed by mitochondrial membrane,
the fluorescence intensity depends on mitochondrial
membrane potential, can be used in analysis of apop-
tosis. As showed in Figure 4B, the fluorescence intensity
was significantly decreased in the PC-3 cells treated with
pcDNA3.1-RBM5 compared with the control groups,
which suggested the dysfunction of mitochondrial mem-
brane potential.
Flow cytometry analysis was used to detect apoptotic
cells which are characterized with phosphatidyl serine
(PS) translocation on the outer cell membrane. Cells
were double-stained with Annexin V and PI after 48 h
transfection. The early and the late apoptotic cells were
distributed in the Q2 and Q3 regions, respectively. The
necrotic cells were located in the Q4 region. Representa-
tive raw FCM data are as follows: cells transfected with
RBM5 showed a higher proportion of early and late
apoptosis (11.16%±2.53% and 1.07%±0.18%) as compared
to the control cells (3.49%±1.17% and 0.81%±0.13%) and
EV cells (3.55%±0.62 and 0.92%±0.15%), respectively
(Figure 4C). The result suggested that overexpression of
RBM5 significant increased apoptosis in PC-3 cells.Figure 5 RBM5 induces apoptosis-related genes expression. Cellular p
pcDNA3.1.1-RBM5 plasmids for 48 h. (A) Expression of Bad, p-Bad, Bid, Bim,
western blot. (B) Quantitative data from A by densitometry using Quantity
to the control and EV groups (P <0.05).RBM5 overexpression was associated with alteration of
apoptosis-related genes
To investigate potential molecular mechanisms under-
lying RBM5-induced cell apoptosis, we next examined
the expression of some apoptosis-related genes in-
cluding P53, Bid, Bim, Bad, p-Bad, cleaved-caspase3, and
cleaved-caspase9. We observed that the expression of
P53, Bim, Bid, p-Bad, cleaved-caspase3, and cleaved-
caspase9 proteins was increased significantly when
RBM5 was overexpressed compared to that in the con-
trol cells (Figure 5). RBM5 might play an import role in
the mitochondrial apoptotic pathway.
Discussion
RBM5 is one of nine genes downregulated in metastasis
and was identified as one of the 17-gene signatures asso-
ciated with metastasis and poor clinical outcomes in
various solid tumor types [22]. RBM5 gene encodes a
number of alternative RNA splice variants with differing
abilities to enhance, sensitize, or suppress apoptosis
[18,23-25]. Other findings show that RBM5-knockdown
upregulated the expression of genes involved in cell ad-
hesion, migration, and motility [26]. RBM5 mRNA was
downregulated in spontaneously developing human
tumors such as human schwannomas [9] as well as in
transformed cells, such as ras-transformed Rat-1 rat em-
bryonic fibroblastic cells [8]. All of these findings suggestroteins were extracted from PC-3 cells transfected with pcDNA3.1 or
P53, cleaved-caspase3, and cleaved-caspase9 were determined by
One software (Bio-Rad). * indicates significant difference as compared
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prognosis, possibly due to tumor progression, metastasis,
and resistance to cancer therapy. In the preliminary
study, our group validated that the expression of RBM5
is lower in human lung cancer tissues than normal tis-
sues did [11], the overexpression of RBM5 inhibit the
proliferation and induce the apoptosis of human lung
cancer A549 cells [15]. But whether the expression levels
of RBM5 have changes in prostate cancer had not been
reported. In this study, we first examined RBM5 protein
expression in prostate cancer tissue and normal prostate
tissue with immunohistochemistry staining. The results
indicated that prostate cancer tissue expressed lower
RBM5 levels than the normal prostate tissue. This im-
plies a correlation between prostate cancer and the ex-
pression of RBM5 and further suggests that RBM5 plays
a critical role in the occurrence and development in
prostate cancer.
In order to explore the role of RBM5 in prostate can-
cer, we transfected pcDNA3.1-RBM5 vector into human
prostate cancer PC-3 cells, and confirmed the overex-
pression of RBM5 RNA and protein by RT-PCR and
western blot. We further observed the changes in PC-3
cells with the RBM5 overexpression, the results showed
that RBM5 overexpression significantly inhibited cell
proliferation and induced apoptosis in PC-3 cells. The
expression of cleaved caspase3 and cleaved caspase9 was
upregulated in pcDNA3.1-RBM5 transfected cells. These
results were similar to our previous findings on lung
cancer and provided evidence that RBM5 might function
as a tumor suppressor and apoptosis inducer for prostate
cancer.
Thus, it is likely that the ability to modulate apop-
tosis is the central to the putative tumor suppressor
activity of RBM5. The increasing evidence showing
the potential molecular mechanism of tumor sup-
pressive activity of RBM5 involves both cell cycle ar-
rest and apoptosis. Tobayashi et al. showed that
RBM5 contributes to p53 transcriptional activity
after DNA damage and that growth suppression and
apoptosis mediated by RBM5 are linked to activity of
the tumor suppressor protein P53 [27]. By western
blot, we observed a significantly increased expression
of wild-type P53, just similar to the results of
Tobayashi et al. Oh et al. showed that the expres-
sion of Bax protein was increased in RBM5-transfected
A549 cells [14]. Bax is a cytosolic monomer in healthy
cells, but it changes conformation during apoptosis, inte-
grates into the outer mitochondrial membrane and oligo-
merizes [28]. How the homo-oligomers form is unclear. It
was reported that the Bax-like proteins could assume both
a ‘BH3 donor’ and a ‘BH3 acceptor’ conformer within the
membrane environment. The BH3-only proteins are senti-
nels that detect developmental death cues or intracellulardamage. In healthy cells, they are restrained in diverse
ways, including sequestration on the cytoskeleton. When
unleashed by death signals, they switch off survival func-
tion by inserting their BH3 domain into a groove on their
pro-survival relatives [29]. In this study, we detected the
member of BH3-only proteins Bid, Bim, Bad, and p-Bad.
The result showed that the expression of cleaved Bid, Bim,
and p-Bad were increased in RBM5-transfected A549 cells.
We demonstrated that BH3-only proteins play critical roles
in RBM5-induced apoptosis.
BH3-only proteins can be activated by transcrip-
tional induction, by post-translational modification
or by liberation from endogenous inhibitors. They
can exert their pro-apoptotic action by different
mechanisms. Individual BH3-only proteins are nor-
mally held in check by diverse mechanisms, and
might transducer specific death signals [30]. Bad pre-
ferentially interact with anti-apoptotic Bcl-2 and Bcl-XL,
dissociating them from BH3 or Bax/Bak-like proteins,
which in turn mediate MMP [31]. Bid is relatively inactive
until proteolytically cleaved. Bid seems to promote death by
activating Bax and Bak to oligomerize and form pores in
the membrane, and it might also inactivate pro-survival
relatives [32]. Bim is sequestered by binding to dynein light
chains that are associated with the microtubules [33]. As
Bim does not bind to Bax or Bak, it must act by preventing
the pro-survival proteins from inhibiting the activation of
Bax and Bak. Along with the study of Oh’s, this study indi-
cated that the overexpression of RBM5 might induce ex-
pression of the BH3-only proteins Bim, p-Bad and cleaved
Bid, BH3-only proteins further engage directly and activate
Bax, this led to changes in the mitochondrial membrane
potential, cytochrome c release into the cytosol, and
enhanced caspase-9 and caspase-3 activities, thereby indu-
cing apoptosis.
Conclusions
In summary, we have shown that RBM5 has a correl-
ation with prostate cancer. The ectopic introduction of
RBM5 can induce the apoptosis of human prostate can-
cer PC-3 cells by modulating the mitochondrial apop-
totic pathway, and thus RBM5 may be a promising
target for gene therapy on prostate cancer.
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